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Table S1 Model parameters 
 Baseline (%) Notes 
Initial population states 
   Operative group   
      Survives after resection  95.4 (373 of 391) Observational data*  
      Dies following resection  4.6 (18 of 391) Observational data* 
   Non-operative group   
        Inoperable patients who receive 
             chemotherapy 
74 (34 of 46) Observational data* 
        Inoperable patients who do not 
             receive chemotherapy 
26 (12 of 46) Observational data* 
   Postoperative complications among 
       patients who die following  
       resection 
83 (15 of 18) Observational data* 
   Survivors after resection who  
       postoperative complications  
14.6 (49 of 335) Observational data* 
   Extrahepatic procedures that are VATS 15 (8 of 52) Observational data* 
Outcome of recurrence 
   Hepatic resection 21.3 (64 of 300) Observational data* 
   Extrahepatic resection 14.3 (43 of 300) Observational data* 
   Non-operable – chemotherapy 47.6 (193 of 300) × (34 of 46) Observational data* 
   Non-operable – no chemotherapy 16.8 (193 of 300) × (12 of 46) Observational data* 
   Proportion of patients dying after  
       resection/extrahepatic procedure 
4.6 (18 of 395) Observational data* 
   Diarrhoea 0.7 Levi et al.
26
; 
assume that this 
proportion of 
patients receiving 
chemotherapy 
suffers diarrhoea at 
any one time 
   Neutropenic fever 2.3 Levi et al.
26
; 
assume that this 
proportion of 
patients receiving 
chemotherapy 
suffers neutropenic 
fever at any one 
time 
The table shows actual outcomes of the patient cohorts. Among 286 patients in the operative cohort a further 
105 operations were performed for recurrent hepatic and extrahepatic disease. *Some patients had more than 
one procedure. VATS, video-assisted thoracoscopic surgery. 
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Table S2 Transition probabilities used in the Markov model at baseline 
 Baseline (probability per  
week) Notes 
Mortality rate among  
   patients receiving  
   chemotherapy 
0.0092 (0.0061) Kaplan–Meier with Greenwood’s formula used to 
obtain s.e. 
Mortality rate among those  
   who die as a result of liver 
   resection/extrahepatic  
   procedure 
0.5527 (0.3336) Assume that death rates for extrahepatic and 
resection procedures are the same 
Mortality rate among  
   inoperable patients 
0.0190 (0.0182) Kaplan–Meier with Greenwood’s formula used to 
obtain s.e. 
Recurrence rate 0.001 (0.00008) Kaplan–Meier with Greenwood’s formula used to 
obtain s.e. 
Mortality rate among patients 
in resection group  
0.0022 (0.0002) Kaplan–Meier with Greenwood’s formula used to 
obtain s.e. 
Values in parentheses are s.e. 
3 
 
Table S3 Utility values used in the Markov model 
 Base-
case 
estimate SA values Source 
Utility after liver resection without morbidity/ 
   mortality during hospitalization postop. 
0.60 ±0.06 van Dam et al.
28
. SA value assumed to 
be within 10% of base-case estimate 
Utility after liver resection without morbidity/ 
   mortality 3 months postop. 
0.74 ±0.074 van Dam et al.
28
. SA value assumed to 
be within 10% of base-case estimate 
Utility after liver resection without morbidity/ 
   mortality 6 months postop. 
0.80 ±0.08 van Dam et al.
28
. SA value assumed to 
be within 10% of base-case estimate 
Utility after liver resection with morbidity during 
   hospitalization postop. 
0.57 ±0.057 van Dam et al.
28
. SA value assumed to 
be within 10% of base-case estimate 
Utility after liver resection with morbidity  
   3 months postop. 
0.71 ±0.071 van Dam et al.
28
. SA value assumed to 
be within 10% of base-case estimate 
Utility after liver resection with morbidity  
   6 months postop. 
0.78 ±0.078 van Dam et al.
28
. SA value assumed to 
be within 10% of base-case estimate 
Utility ≥ 1 year postop. (both liver resection and  
   extrahepatic procedure) 
0.83 Range 0.17–1.00 Tanis et al.29 
Extrahepatic procedure during hospitalization  
   postop. 
0.6 ±0.06 Assumed to be the same as resection 
Extrahepatic procedure – VATS 3 months postop. 0.73 s.d. 0.18 Iwahashi et al.30 
Extrahepatic procedure – VATS 6 months postop. 0.75 s.d. 0.19 Iwahashi et al.30 
Extrahepatic procedure – non-VATS 3 months  
   postop. 
0.72 s.d. 0.25 Iwahashi et al.
30
 
Extrahepatic procedure – non-VATS 6 months  
    postop. 
0.77 s.d. 0.24 Iwahashi et al.
30
 
Utility during chemotherapy 0.68 Plausible range 
0.54–0.82 
Levi et al.
26 
Neutropenic fever (2.3%) 0.47 Plausible range 
0.38–0.56 
Levi et al.
26
 
Grade 3–4 diarrhoea (0.7%) 0.32 Plausible range 
0.26–0.38 
Levi et al.
26
 
Inoperable (palliative treatments) 0.63 Plausible range 
0.50–0.76 
Levi et al.
26
 
SA, sensitivity analysis; VATS, video-assisted thoracoscopic surgery. 
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Fig. 1 Structure of Markov model for operative strategy. Hepatic resection and extrahepatic resection states were further stratified into 
hospitalized (live and die), within 6 months postop. and within 12 months postop., with these states subdivided into with or without 
complications. All model states are subject to colorectal cancer-related and background mortality. Recurrence is an event rather than a model 
state 
Recurrence 
Extra-
hepatic 
resection 
Inoperable- 
Chemotherapy 
Inoperable- 
No 
Chemotherapy 
1+ Years 
Post-
Operation 
Hepatic 
Resection 
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Table S4 Distributions used in the probabilistic sensitivity analysis 
 Distribution a b 
Proportion of inoperable patients who receive chemotherapy Beta 46 34 
Proportion of those who die following a resection and have 
complications 
Beta 18 3 
Proportion of those who live following a resection and have 
complications 
Beta 335 49 
CT scans per week for patients following the inoperable strategy Beta 625 29 
Outpatient appointments  per week for patients following the 
inoperable strategy 
Beta 625 187 
MRI scans per week for patients following inoperable strategy Beta 625 7 
Proportion of extrahepatic procedures that are VATS Beta 52 8 
Proportion who die following a resection or extrahepatic 
procedure 
Beta 395 18 
Probability of recurrence among patients following the operable 
strategy 
Beta 224.73 1887050.3 
Probability of disease-related mortality for patients on 
chemotherapy 
Beta 2.24 242.10 
Weekly probability of death among patients who die following 
an extrahepatic procedure (informs hospital stay until death) 
Beta 1.23 0.99 
Weekly probability of leaving hospital following extrahepatic 
procedures and resection (informs postop. hospital stay) 
Beta 3.90 4.12 
Probability of disease-related mortality for those inoperable not 
receiving chemotherapy 
Beta 1.07 55.29 
Probability of disease-related mortality among patients 
following operable strategy 
Beta 93.73 42247.17 
Proportion of patients with postop. neutropenic fever Beta 0.98 41.50 
Proportion of patients with postop. diarrhoea Beta 258.41 549.12 
Utility among inoperable patients who do not receive 
chemotherapy 
Beta 637.93 374.66 
Utility among patients receiving chemotherapy Beta 428.11 201.46 
Utility during postop. inpatient stay without complications Beta 235.81 157 
Utility during postop. inpatient stay with complications Beta 211.65 159.60 
Utility for patients 3 months after extrahepatic procedure with 
VATS 
Beta 4.44 1.64 
Utility for patients 6 months after extrahepatic procedure with 
VATS 
Beta 3.90 1.30 
Utility for patients 3 months after non-VATS extrahepatic 
procedure  
Beta 2.32 0.90 
Utility for patients 6 months after non-VATS extrahepatic 
procedure  
Beta 2.37 0.71 
Utility for patients 3 months after resection, no complications Beta 163.92 57.46 
Utility for patients 6 months after resection, no complications Beta 140.28 34.93 
Utility for patients 3 months after resection, complications Beta 123.43 50.40 
Utility for patients 6 months after resection, complications Beta 129.02 36.37 
Utility for patients > 1 year after procedure Beta 9.76 2 
Utility for patients with neutropenic fever Beta 516.23 582.13 
Utility for patients with diarrhoea Beta 258.41 549.12 
Cost of chemotherapy (weekly) (€) Normal Mean 430 s.e. 64.79 
Cost of postresection hospital stay (variation due to different 
initial procedure being implemented) (€) 
Normal Mean 2886.61 s.e. 24.65 
Cost of resection procedure (€) Normal Mean 7132.12 s.e. 93.78 
Two parameters are used to describe the beta distribution, a and b. The beta (a, b) distribution can be used to 
precisely represent uncertainly in a proportion when the only available information is the number of positive 
cases (a) and negative cases (b). In this study, where exact numbers were available, these were used to inform 
the parameters of each beta distribution. Where only mean and s.e. values were available, the method of 
moments was used to estimate a and b. VATS, video-assisted thoracoscopic surgery.  
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Fig. S2 Scatter plots and cost-effectiveness acceptability curves for the probabilistic sensitivity analysis, 
assuming that: a,b there are no postoperative deaths following initial resection in the operative pathway; c,d all 
patients in the non-operative pathway receive chemotherapy; e,f there are no postoperative deaths following 
initial resection in the operative pathway and all patients in the non-operative pathway receive chemotherapy; 
and g,h all patients in the operative pathway have involved surgical margins (all patients with clear (R0) 
resection margins were excluded from analyses). In all these examples it can be seen that the conclusions drawn 
from the model are robust and that the operative strategy is certain to be the most cost-effective option for a 
willingness-to-pay (WTP) for 1 quality-adjusted life-year (QALY) of €6000 or more 
 
 
 
Fig. S3 Scatter plot and cost-effectiveness acceptability curve for the probabilistic sensitivity analysis assuming 
that there were no survivors at 10 years in the operative pathway. For a willingness-to-pay (WTP) for 1 quality-
adjusted life-year (QALY) of less than €50 000, the operative strategy is still more than 90 per cent likely to be 
the most cost-effective strategy, and more than 80 per cent likely to be cost-effective for a WTP of up to 
€100 000  per QALY (steady state value 79.4 per cent) 
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